DYNE THERAPEUTICS INC (DYN)

US26818M1080 - Common Stock

26.08  +0.08 (+0.31%)

After market: 26.08 0 (0%)

Fundamental Rating

2

Taking everything into account, DYN scores 2 out of 10 in our fundamental rating. DYN was compared to 588 industry peers in the Biotechnology industry. While DYN has a great health rating, there are worries on its profitability. DYN has a expensive valuation and it also scores bad on growth.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

DYN had negative earnings in the past year.
In the past year DYN has reported a negative cash flow from operations.
DYN had negative earnings in each of the past 5 years.
DYN had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

DYN has a Return On Assets of -142.92%. This is amonst the worse of the industry: DYN underperforms 85.15% of its industry peers.
With a Return On Equity value of -258.44%, DYN is not doing good in the industry: 72.35% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -142.92%
ROE -258.44%
ROIC N/A
ROA(3y)-77.62%
ROA(5y)-68.06%
ROE(3y)-121.86%
ROE(5y)-97.82%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DYN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for DYN has been increased compared to 1 year ago.
DYN has more shares outstanding than it did 5 years ago.
DYN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 8.58 indicates that DYN is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 8.58, DYN belongs to the best of the industry, outperforming 84.81% of the companies in the same industry.
DYN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.58
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 2.53 indicates that DYN has no problem at all paying its short term obligations.
With a Current ratio value of 2.53, DYN is not doing good in the industry: 72.87% of the companies in the same industry are doing better.
A Quick Ratio of 2.53 indicates that DYN has no problem at all paying its short term obligations.
DYN's Quick ratio of 2.53 is on the low side compared to the rest of the industry. DYN is outperformed by 70.48% of its industry peers.
Industry RankSector Rank
Current Ratio 2.53
Quick Ratio 2.53

More info and screens

1

3. Growth

3.1 Past

The earnings per share for DYN have decreased strongly by -21.60% in the last year.
EPS 1Y (TTM)-21.6%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-47.3%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 13.47% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y15.59%
EPS Next 2Y7.74%
EPS Next 3Y9.05%
EPS Next 5Y13.47%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

DYN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year DYN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.74%
EPS Next 3Y9.05%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DYN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DYNE THERAPEUTICS INC

NASDAQ:DYN (5/3/2024, 3:30:02 PM)

After market: 26.08 0 (0%)

26.08

+0.08 (+0.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.25B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -142.92%
ROE -258.44%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.53
Quick Ratio 2.53
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-21.6%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y15.59%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y